December 3, 2018 / 6:18 AM / in 15 days

BRIEF-Roche Announces Polatuzumab Study Data On Lymphoma Treatment

Dec 3 (Reuters) - Roche Holding AG:

* LONGER-TERM FOLLOW-UP DATA DEMONSTRATE SUSTAINED BENEFIT OF POLATUZUMAB VEDOTIN-BASED TREATMENT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

* POLATUZUMAB VEDOTIN IN COMBINATION WITH MABTHERA/RITUXAN (RITUXIMAB) PLUS BENDAMUSTINE MORE THAN DOUBLED OVERALL SURVIVAL, COMPARED TO MABTHERA/RITUXAN PLUS BENDAMUSTINE ALONE IN THE PHASE IB/II GO29365 STUDY

* POLATUZUMAB VEDOTIN HAS THE POTENTIAL TO PROVIDE A PROMISING NEW TREATMENT OPTION AT FIRST RELAPSE

* RESULTS FROM THE GO29365 STUDY WILL BE SUBMITTED TO HEALTH AUTHORITIES AROUND THE WORLD FOR APPROVAL CONSIDERATION Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below